Nicergoline in the treatment of dizziness in elderly patients. A review

G. Felisati, O. Pignataro, A. Di Girolamo, E. Bruno, M. Alessandrini, G. Guidetti, D. Monzani, A. M. Beldi, E. Mira, M. Benazzo, E. Pallestrini, G. Caligo, A. Casani, A. Battaglia

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In elderly patients, dizziness occurs very frequently with significant effects on the patient's life. Its frequency increases with age, and may arise from a variety of causes. Chronic dysequilibrium in elderly patients is most probably related to disturbances within the central nervous system, due either to altered neuronal functions or to an underlying vascular disease. Nicergoline, a drug used in the treatment of cognitive disturbances in geriatric patients, improves dizziness in elderly demented and non-demented patients. In a double-blind, placebo controlled trial the drug improved (i) the severity of symptoms, measured by the dizziness assessment rating scale (DARS), (ii) the overall clinical conditions revealed by global impression scale, and (iii) the perceived quality of life estimated by the dizziness handicap inventory (DHI). These results indicate a possible positive effect also on posturographic measures. Moreover, the improvement occurred at no expense of the established strategy of postural control suggesting that the effect is mediated by a substitute compensatory mechanism allowing the patient to preserve consolidated postural strategies. The results of previous open clinical studies in about 3000 patients are in agreement with those findings. Overall, severity of symptoms decreased by 68 % (57 % in the control study). Globally, the results indicate a beneficial effect of nicergoline on symptoms related to balance disorders of central origin. Animal studies show that the drug displays a broad spectrum of actions on cellular and molecular mechanisms. Moreover, animal research specifically aimed at vestibular pathophysiology has revealed that nicergoline improves vestibular compensation in models of vestibular lesion. Chronic treatment with nicergoline improved the time-course of behavioral recovery in old rats after hemi-labyrinthectomy and counteracted the regulation of cholinergic receptors observed after lesion in old rats. Nicergoline interacts at several levels by various mechanisms, from the molecular level to cognitive function, probably enhancing spontaneous plasticity phenomena underlying the central vestibular compensation. This effect is not dependent from the interaction with a single-transmitter-identified neural pathway, but from anatomical, functional and neurochemical synergistic adiustments in several brain areas.

Original languageEnglish
Pages (from-to)163-170
Number of pages8
JournalArchives of Gerontology and Geriatrics
Volume38
Issue numberSUPPL.
DOIs
Publication statusPublished - 2004

Fingerprint

Nicergoline
Dizziness
drug
animal
Therapeutics
Handicap
geriatrics
rating scale
Pharmaceutical Preparations
Neural Pathways
quality of life
brain
Cholinergic Receptors
Vascular Diseases
Geriatrics
Disease
Cognition
regulation
cause
Central Nervous System

Keywords

  • Dizziness in elderly
  • Nicergoline treatment
  • Vestibular compensation

ASJC Scopus subject areas

  • Ageing
  • Medicine(all)

Cite this

Felisati, G., Pignataro, O., Di Girolamo, A., Bruno, E., Alessandrini, M., Guidetti, G., ... Battaglia, A. (2004). Nicergoline in the treatment of dizziness in elderly patients. A review. Archives of Gerontology and Geriatrics, 38(SUPPL.), 163-170. https://doi.org/10.1016/j.archger.2004.04.023

Nicergoline in the treatment of dizziness in elderly patients. A review. / Felisati, G.; Pignataro, O.; Di Girolamo, A.; Bruno, E.; Alessandrini, M.; Guidetti, G.; Monzani, D.; Beldi, A. M.; Mira, E.; Benazzo, M.; Pallestrini, E.; Caligo, G.; Casani, A.; Battaglia, A.

In: Archives of Gerontology and Geriatrics, Vol. 38, No. SUPPL., 2004, p. 163-170.

Research output: Contribution to journalArticle

Felisati, G, Pignataro, O, Di Girolamo, A, Bruno, E, Alessandrini, M, Guidetti, G, Monzani, D, Beldi, AM, Mira, E, Benazzo, M, Pallestrini, E, Caligo, G, Casani, A & Battaglia, A 2004, 'Nicergoline in the treatment of dizziness in elderly patients. A review', Archives of Gerontology and Geriatrics, vol. 38, no. SUPPL., pp. 163-170. https://doi.org/10.1016/j.archger.2004.04.023
Felisati G, Pignataro O, Di Girolamo A, Bruno E, Alessandrini M, Guidetti G et al. Nicergoline in the treatment of dizziness in elderly patients. A review. Archives of Gerontology and Geriatrics. 2004;38(SUPPL.):163-170. https://doi.org/10.1016/j.archger.2004.04.023
Felisati, G. ; Pignataro, O. ; Di Girolamo, A. ; Bruno, E. ; Alessandrini, M. ; Guidetti, G. ; Monzani, D. ; Beldi, A. M. ; Mira, E. ; Benazzo, M. ; Pallestrini, E. ; Caligo, G. ; Casani, A. ; Battaglia, A. / Nicergoline in the treatment of dizziness in elderly patients. A review. In: Archives of Gerontology and Geriatrics. 2004 ; Vol. 38, No. SUPPL. pp. 163-170.
@article{6a8f0eede66f43acbd5ecb1b261c312c,
title = "Nicergoline in the treatment of dizziness in elderly patients. A review",
abstract = "In elderly patients, dizziness occurs very frequently with significant effects on the patient's life. Its frequency increases with age, and may arise from a variety of causes. Chronic dysequilibrium in elderly patients is most probably related to disturbances within the central nervous system, due either to altered neuronal functions or to an underlying vascular disease. Nicergoline, a drug used in the treatment of cognitive disturbances in geriatric patients, improves dizziness in elderly demented and non-demented patients. In a double-blind, placebo controlled trial the drug improved (i) the severity of symptoms, measured by the dizziness assessment rating scale (DARS), (ii) the overall clinical conditions revealed by global impression scale, and (iii) the perceived quality of life estimated by the dizziness handicap inventory (DHI). These results indicate a possible positive effect also on posturographic measures. Moreover, the improvement occurred at no expense of the established strategy of postural control suggesting that the effect is mediated by a substitute compensatory mechanism allowing the patient to preserve consolidated postural strategies. The results of previous open clinical studies in about 3000 patients are in agreement with those findings. Overall, severity of symptoms decreased by 68 {\%} (57 {\%} in the control study). Globally, the results indicate a beneficial effect of nicergoline on symptoms related to balance disorders of central origin. Animal studies show that the drug displays a broad spectrum of actions on cellular and molecular mechanisms. Moreover, animal research specifically aimed at vestibular pathophysiology has revealed that nicergoline improves vestibular compensation in models of vestibular lesion. Chronic treatment with nicergoline improved the time-course of behavioral recovery in old rats after hemi-labyrinthectomy and counteracted the regulation of cholinergic receptors observed after lesion in old rats. Nicergoline interacts at several levels by various mechanisms, from the molecular level to cognitive function, probably enhancing spontaneous plasticity phenomena underlying the central vestibular compensation. This effect is not dependent from the interaction with a single-transmitter-identified neural pathway, but from anatomical, functional and neurochemical synergistic adiustments in several brain areas.",
keywords = "Dizziness in elderly, Nicergoline treatment, Vestibular compensation",
author = "G. Felisati and O. Pignataro and {Di Girolamo}, A. and E. Bruno and M. Alessandrini and G. Guidetti and D. Monzani and Beldi, {A. M.} and E. Mira and M. Benazzo and E. Pallestrini and G. Caligo and A. Casani and A. Battaglia",
year = "2004",
doi = "10.1016/j.archger.2004.04.023",
language = "English",
volume = "38",
pages = "163--170",
journal = "Archives of Gerontology and Geriatrics",
issn = "0167-4943",
publisher = "Elsevier Ireland Ltd",
number = "SUPPL.",

}

TY - JOUR

T1 - Nicergoline in the treatment of dizziness in elderly patients. A review

AU - Felisati, G.

AU - Pignataro, O.

AU - Di Girolamo, A.

AU - Bruno, E.

AU - Alessandrini, M.

AU - Guidetti, G.

AU - Monzani, D.

AU - Beldi, A. M.

AU - Mira, E.

AU - Benazzo, M.

AU - Pallestrini, E.

AU - Caligo, G.

AU - Casani, A.

AU - Battaglia, A.

PY - 2004

Y1 - 2004

N2 - In elderly patients, dizziness occurs very frequently with significant effects on the patient's life. Its frequency increases with age, and may arise from a variety of causes. Chronic dysequilibrium in elderly patients is most probably related to disturbances within the central nervous system, due either to altered neuronal functions or to an underlying vascular disease. Nicergoline, a drug used in the treatment of cognitive disturbances in geriatric patients, improves dizziness in elderly demented and non-demented patients. In a double-blind, placebo controlled trial the drug improved (i) the severity of symptoms, measured by the dizziness assessment rating scale (DARS), (ii) the overall clinical conditions revealed by global impression scale, and (iii) the perceived quality of life estimated by the dizziness handicap inventory (DHI). These results indicate a possible positive effect also on posturographic measures. Moreover, the improvement occurred at no expense of the established strategy of postural control suggesting that the effect is mediated by a substitute compensatory mechanism allowing the patient to preserve consolidated postural strategies. The results of previous open clinical studies in about 3000 patients are in agreement with those findings. Overall, severity of symptoms decreased by 68 % (57 % in the control study). Globally, the results indicate a beneficial effect of nicergoline on symptoms related to balance disorders of central origin. Animal studies show that the drug displays a broad spectrum of actions on cellular and molecular mechanisms. Moreover, animal research specifically aimed at vestibular pathophysiology has revealed that nicergoline improves vestibular compensation in models of vestibular lesion. Chronic treatment with nicergoline improved the time-course of behavioral recovery in old rats after hemi-labyrinthectomy and counteracted the regulation of cholinergic receptors observed after lesion in old rats. Nicergoline interacts at several levels by various mechanisms, from the molecular level to cognitive function, probably enhancing spontaneous plasticity phenomena underlying the central vestibular compensation. This effect is not dependent from the interaction with a single-transmitter-identified neural pathway, but from anatomical, functional and neurochemical synergistic adiustments in several brain areas.

AB - In elderly patients, dizziness occurs very frequently with significant effects on the patient's life. Its frequency increases with age, and may arise from a variety of causes. Chronic dysequilibrium in elderly patients is most probably related to disturbances within the central nervous system, due either to altered neuronal functions or to an underlying vascular disease. Nicergoline, a drug used in the treatment of cognitive disturbances in geriatric patients, improves dizziness in elderly demented and non-demented patients. In a double-blind, placebo controlled trial the drug improved (i) the severity of symptoms, measured by the dizziness assessment rating scale (DARS), (ii) the overall clinical conditions revealed by global impression scale, and (iii) the perceived quality of life estimated by the dizziness handicap inventory (DHI). These results indicate a possible positive effect also on posturographic measures. Moreover, the improvement occurred at no expense of the established strategy of postural control suggesting that the effect is mediated by a substitute compensatory mechanism allowing the patient to preserve consolidated postural strategies. The results of previous open clinical studies in about 3000 patients are in agreement with those findings. Overall, severity of symptoms decreased by 68 % (57 % in the control study). Globally, the results indicate a beneficial effect of nicergoline on symptoms related to balance disorders of central origin. Animal studies show that the drug displays a broad spectrum of actions on cellular and molecular mechanisms. Moreover, animal research specifically aimed at vestibular pathophysiology has revealed that nicergoline improves vestibular compensation in models of vestibular lesion. Chronic treatment with nicergoline improved the time-course of behavioral recovery in old rats after hemi-labyrinthectomy and counteracted the regulation of cholinergic receptors observed after lesion in old rats. Nicergoline interacts at several levels by various mechanisms, from the molecular level to cognitive function, probably enhancing spontaneous plasticity phenomena underlying the central vestibular compensation. This effect is not dependent from the interaction with a single-transmitter-identified neural pathway, but from anatomical, functional and neurochemical synergistic adiustments in several brain areas.

KW - Dizziness in elderly

KW - Nicergoline treatment

KW - Vestibular compensation

UR - http://www.scopus.com/inward/record.url?scp=3042594194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042594194&partnerID=8YFLogxK

U2 - 10.1016/j.archger.2004.04.023

DO - 10.1016/j.archger.2004.04.023

M3 - Article

AN - SCOPUS:3042594194

VL - 38

SP - 163

EP - 170

JO - Archives of Gerontology and Geriatrics

JF - Archives of Gerontology and Geriatrics

SN - 0167-4943

IS - SUPPL.

ER -